The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Docetaxel is the main treatment for advanced castration‐resistant prostate cancer; however, resistance eventually occurs. The development of intratumoral drug‐resistant subpopulations possessing a cancer stem cell (CSC) morphology is an emerging mechanism of docetaxel resistance, a process driven by epithelial–mesenchymal transition (EMT). This study characterised EMT in docetaxel‐resistant sublines through increased invasion, MMP‐1 production and ZEB 1 and ZEB 2 expression. We also present evidence for differential EMT across PC‐3 and DU 145 in vitro resistance models as characterised by differential migration, cell colony scattering and susceptibility to the CSC inhibitor salinomycin. si RNA manipulation of ZEB 1 and ZEB 2 in PC‐3 and DU 145 docetaxel‐resistant sublines identified ZEB 1, through its transcriptional repression of E‐cadherin, to be a driver of both EMT and docetaxel resistance. The clinical relevance of ZEB 1 was also determined through immunohistochemical tissue microarray assessment, revealing significantly increased ZEB 1 expression in prostate tumours following docetaxel treatment. This study presents evidence for a role of ZEB 1, through its transcriptional repression of E‐cadherin to be a driver of both EMT and docetaxel resistance in docetaxel‐resistant prostate cancer. In addition, this study highlights the heterogeneity of prostate cancer and in turn emphasises the complexity of the clinical management of docetaxel‐resistant prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“However, docetaxel provides a modest survival advantage of approximately two months compared to other treatment strategies due to the emergence of drug resistance (Tannock et al., 2004).”
BackgroundMatrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302 · cited 4×
“Studies have demonstrated the ability of EMT to activate a reversion of tumour cells to a CSC-like morphology (Mani et al., 2008; Polyak and Weinberg, 2009), with docetaxel-resistant prostate cancer cells displaying both an EMT and CSC-like morphology, through increased expression of the CSC marker…”
BackgroundInfluentialSnail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · cited 2×
“Loss of E-cadherin is initiated by the ZEB (ZEB1 and ZEB2) family of transcription factors (Peinado et al., 2007) which bind to E-box elements within the promoter region of the E-cadherin (CDH1) gene (Hill et al.”
BackgroundEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 4×
“, 2013) and through recruitment of histone deacetylases and chromatin condensation achieve transcriptional repression of E-cadherin (Singh and Settleman, 2010) and in turn initiate EMT.”
BackgroundInfluentialCancer Invasion and the Microenvironment: Plasticity and Reciprocity
Friedl, P., & Alexander, S. (2011) · Cell · doi:10.1016/j.cell.2011.11.016 · Cited by 1,940 · cited 2×
“This switch from a collective to single-cell migration is characteristic of mesenchymal cells to facilitate dissemination into the bloodstream (Friedl and Alexander, 2011; Giampieri et al., 2009).”
BackgroundFischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Cited by
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
“A deregulation of the miR-200 family/ZEBs axis appears to mediate docetaxel resistance of prostate cancer cells (Hanrahan et al., 2017; Puhr et al., 2012).”
BackgroundHybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas
Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., Hanash, S. M., Bapat, S. A., Rangarajan, A., & Levine, H. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.007 · Cited by 333
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T. M., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 268
Alternative mechanisms of miR-34a regulation in cancer
Slabáková, E., Culig, Z., Remšík, J., & Souček, K. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.495 · Cited by 264
Self-citationMechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Metadata
- Authors
- Hanrahan, K., O'Neill, A., Prencipe, M., Bugler, J., Murphy, L., Fabre, A., Puhr, M., Culig, Z., Murphy, K., & Watson, R. W.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2017-01-30
- Volume
- 11
- Issue
- 3
- Pages
- 251-265
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2582775233
- Cited by
- 124
- References
- 8
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer. https://app.cochat.ai/papers/10.1002/1878-0261.12030
- The paper
- Hanrahan, K., O'Neill, A., Prencipe, M., Bugler, J., Murphy, L., Fabre, A., Puhr, M., Culig, Z., Murphy, K., & Watson, R. W. (2017). The role of epithelial–mesenchymal transition drivers ZEB 1 and ZEB 2 in mediating docetaxel‐resistant prostate cancer. Molecular Oncology. https://doi.org/10.1002/1878-0261.12030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.